{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:16:21Z","timestamp":1778868981453,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["MD200001"],"award-info":[{"award-number":["MD200001"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtm.2025.101515","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:20:06Z","timestamp":1750101606000},"page":"101515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ubiquitination-targeted therapies improve BMD iPSC myogenic cell engraftment and dystrophin expression in vivo"],"prefix":"10.1016","volume":"33","author":[{"given":"Muchen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somik","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab","family":"Kashaniasl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6830-9969","authenticated-orcid":false,"given":"Radbod","family":"Darabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101515_bib1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101515_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101515_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","article-title":"Duchenne and Becker muscular dystrophies","volume":"32","author":"Flanigan","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.omtm.2025.101515_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2025.101515_bib5","first-page":"14","article-title":"Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies","volume":"15","author":"Le Rumeur","year":"2015","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.omtm.2025.101515_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.bmb.a072351","article-title":"Molecular analysis of Duchenne and Becker muscular dystrophies","volume":"45","author":"Love","year":"1989","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.omtm.2025.101515_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/WCO.0000000000000739","article-title":"Update in Duchenne and Becker muscular dystrophy","volume":"32","author":"Waldrop","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.omtm.2025.101515_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/WCO.0000000000001191","article-title":"An update on Becker muscular dystrophy","volume":"36","author":"Straub","year":"2023","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.omtm.2025.101515_bib9","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/acn3.51925","article-title":"Natural history of Becker muscular dystrophy: a multicenter study of 225 patients","volume":"10","author":"Nakamura","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2025.101515_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF00858725","article-title":"The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history","volume":"240","author":"Bushby","year":"1993","journal-title":"J. Neurol."},{"key":"10.1016\/j.omtm.2025.101515_bib11","first-page":"172","article-title":"Current and emerging therapies in Becker muscular dystrophy (BMD)","volume":"38","author":"Angelini","year":"2019","journal-title":"Acta Myol."},{"key":"10.1016\/j.omtm.2025.101515_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/neurolint16040055","article-title":"Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy","volume":"16","author":"Krishna","year":"2024","journal-title":"Neurol. Int."},{"key":"10.1016\/j.omtm.2025.101515_bib13","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/jama.2024.5613","article-title":"The FDA and Gene Therapy for Duchenne Muscular Dystrophy","volume":"331","author":"Rind","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.omtm.2025.101515_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100800","article-title":"CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2025.101515_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/jpm9010016","article-title":"Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy","volume":"9","author":"Nakamura","year":"2019","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.omtm.2025.101515_bib16","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41556-020-00595-5","article-title":"The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin","volume":"22","author":"Zhang","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtm.2025.101515_bib17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41556-020-00598-2","article-title":"H19 lncRNA to dystrophin's rescue","volume":"22","author":"Ritso","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtm.2025.101515_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13073-021-00937-4","article-title":"Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects","volume":"13","author":"Li","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.omtm.2025.101515_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymthe.2020.09.012","article-title":"Evaluation of the Therapeutic Potential of Human iPSCs in a Murine Model of VML","volume":"29","author":"Wu","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101515_bib20","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.celrep.2018.10.067","article-title":"A Myogenic Double-Reporter Human Pluripotent Stem Cell Line Allows Prospective Isolation of Skeletal Muscle Progenitors","volume":"25","author":"Wu","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2025.101515_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102746","article-title":"Directed Differentiation of Human Pluripotent Stem Cells toward Skeletal Myogenic Progenitors and Their Purification Using Surface Markers","volume":"10","author":"Xu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2025.101515_bib22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.omtn.2023.07.037","article-title":"Disease modeling and gene correction of LGMDR21 iPSCs elucidates the role of POGLUT1 in skeletal muscle maintenance, regeneration, and the satellite cell niche","volume":"33","author":"Ortiz-Vitali","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2025.101515_bib23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.stem.2012.02.015","article-title":"Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice","volume":"10","author":"Darabi","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtm.2025.101515_bib24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/bmj.1.5397.1553","article-title":"Trial of Nifenazone (\"Thylin\")","volume":"1","author":"Hart","year":"1964","journal-title":"Br. Med. J."},{"key":"10.1016\/j.omtm.2025.101515_bib25","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1073\/pnas.1804198115","article-title":"Small molecule inhibits alpha-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons","volume":"115","author":"Pujols","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101515_bib26","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00726-018-2614-7","article-title":"Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications","volume":"50","author":"Hanff","year":"2018","journal-title":"Amino Acids"},{"key":"10.1016\/j.omtm.2025.101515_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00726-024-03383-9","article-title":"GC-MS analysis of 4-hydroxyproline: elevated proline hydroxylation in metformin-associated lactic acidosis and metformin-treated Becker muscular dystrophy patients","volume":"56","author":"Baskal","year":"2024","journal-title":"Amino Acids"},{"key":"10.1016\/j.omtm.2025.101515_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004327","article-title":"Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy","volume":"4","author":"Martin","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101515_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1095121","article-title":"Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study","volume":"14","author":"Comi","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtm.2025.101515_bib30","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201367","article-title":"Proteins implicated in muscular dystrophy and cancer are functional constituents of the centrosome","volume":"5","author":"Winter","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omtm.2025.101515_bib31","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101515_bib32","article-title":"Cellular pathogenesis of Duchenne muscular dystrophy: progressive myofibre degeneration, chronic inflammation, reactive myofibrosis and satellite cell dysfunction","volume":"33","author":"Dowling","year":"2023","journal-title":"Eur. J. Transl. Myol."},{"key":"10.1016\/j.omtm.2025.101515_bib33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.molmed.2016.04.002","article-title":"Satellite Cells in Muscular Dystrophy - Lost in Polarity","volume":"22","author":"Chang","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtm.2025.101515_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73315-6","article-title":"Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy","volume":"10","author":"Sugihara","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2025.101515_bib35","article-title":"Mitochondrial Dysfunction as an Underlying Cause of Skeletal Muscle Disorders","volume":"23","author":"Chen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101515_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lfs.2017.11.035","article-title":"Altered membrane integrity in the progression of muscle diseases","volume":"192","author":"McElhanon","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.omtm.2025.101515_bib37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.RES.0000126574.61061.25","article-title":"The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma","volume":"94","author":"Lapidos","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtm.2025.101515_bib38","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.75521","article-title":"Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts","volume":"11","author":"Gosselin","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.omtm.2025.101515_bib39","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/hmg\/ddn151","article-title":"Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy","volume":"17","author":"Kimura","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101515_bib40","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jcsm.13171","article-title":"The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47","volume":"14","author":"Heier","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtm.2025.101515_bib41","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.100665","article-title":"Becker muscular dystrophy mice showed site-specific decay of type IIa fibers with capillary change in skeletal muscle","volume":"13","author":"Miyazaki","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.omtm.2025.101515_bib42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4330\/wjc.v8.i6.356","article-title":"Cardiomyopathy in becker muscular dystrophy: Overview","volume":"8","author":"Ho","year":"2016","journal-title":"World J. Cardiol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012500110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012500110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:56:09Z","timestamp":1778867769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012500110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S232905012500110X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101515","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ubiquitination-targeted therapies improve BMD iPSC myogenic cell engraftment and dystrophin expression in vivo","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101515"}}